CytomX Therapeutics(NASDAQ) CTMX
| Metric | Price | Date |
|---|---|---|
| Last close | USD 3.33 | 2026-07-22 |
| Period | Price return | Price at period start | Period start date |
|---|---|---|---|
| 1 week | -9.51% | USD 3.68 | 2026-07-15 |
| 1 month | +9.54% | USD 3.04 | 2026-06-22 |
| 3 month | -25.17% | USD 4.45 | 2026-04-23 |
| Year to date | -21.83% | USD 4.26 | 2025-12-31 |
| 1 year | +39.33% | USD 2.39 | 2025-07-22 |
| 3 year | +86.03% | USD 1.79 | 2023-07-21 |
| 5 year | -40% | USD 5.55 | 2021-07-23 |
| Since inception | -74.19% | USD 12.90 | 2015-10-08 |
CytomX Therapeutics Financials at a Glance
Market Cap
Revenue (TTM)
Net Income (TTM)
EPS (TTM)
P/E Ratio
Dividend
Beta (Volatility)
Dividend
Beta (Volatility)
Price
Volume
Open
Price
Volume
Open
Previous Close
Daily Range
52-Week Range
Estimated Earnings Date
Dividend
Beta (Volatility)
Price
Volume
Open
Previous Close
Daily Range
52-Week Range
Estimated Earnings Date
CTMX News
CTMX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout CytomX Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
69
CEO
Sean A. McCarthy, PhD, MBA
Website
www.cytomx.comHeadquarters
South San Francisco, CA 94080, US
CTMX Financials
Key Financial Metrics (TTM)
Gross Margin
Operating Margin
Net Income Margin
Return on Equity
Return on Capital
Return on Assets
Earnings Yield
Dividend Yield
Payout Ratio
Stock Overview
Market Cap
Shares Outstanding
Volume
Avg. Volume
Financials (TTM)
Gross Profit
Operating Income
EBITDA
Operating Cash Flow
Capital Expenditure
Free Cash Flow
Cash & ST Invst.
Total Debt
CytomX Therapeutics Performance Analysis
| Fiscal year | Period end | Revenue | YoY growth |
|---|---|---|---|
| 2022 | 2022-12-31 | USD 53,163,000 | 42.5% |
| 2023 | 2023-12-31 | USD 101,214,000 | 90.4% |
| 2024 | 2024-12-31 | USD 138,103,000 | 36.4% |
| 2025 | 2025-12-31 | USD 76,201,000 | -44.8% |
| Fiscal quarter | Period end | QoQ growth |
|---|---|---|
| Q2 | 2025-06-30 | -63.4% |
| Q3 | 2025-09-30 | -68.0% |
| Q4 | 2025-12-31 | -88.9% |
| Q1 | 2026-03-31 | 1447.2% |
| Fiscal year | Period end | Diluted EPS | YoY growth |
|---|---|---|---|
| 2022 | 2022-12-31 | USD -1.51 | -16.4% |
| 2023 | 2023-12-31 | USD -0.01 | -99.5% |
| 2024 | 2024-12-31 | USD 0.38 | N/A |
| 2025 | 2025-12-31 | USD -0.15 | N/A |
| Fiscal quarter | Period end | QoQ growth |
|---|---|---|
| Q2 | 2025-06-30 | -100.4% |
| Q3 | 2025-09-30 | -7400.0% |
| Q4 | 2025-12-31 | -88.9% |
| Q1 | 2026-03-31 | 41.2% |
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
-79.9%
Gross Profit
-80.3%
Gross Margin
N/A
Market Cap
N/A
Market Cap/Employee
N/A
Employees
N/A
Net Income
-177.6%
EBITDA
-174.8%
Quarterly Fundamentals
Total Cash
+334.0%
Total Debt
-65.0%
Accounts Receivable
-67.0%
Inventory
N/A
Long Term Debt
-100.0%
Short Term Debt
-46.0%
Return on Assets
N/A
Return on Invested Capital
N/A
Free Cash Flow
-20.7%
Operating Cash Flow
-21.4%